Last reviewed · How we verify
Glycerol "OBA"
Glycerol acts as an osmotic agent that draws fluid into the intracellular and extracellular spaces, reducing intracranial pressure and edema.
Glycerol acts as an osmotic agent that draws fluid into the intracellular and extracellular spaces, reducing intracranial pressure and edema. Used for Elevated intracranial pressure, Cerebral edema.
At a glance
| Generic name | Glycerol "OBA" |
|---|---|
| Sponsor | University of Aarhus |
| Drug class | Osmotic diuretic |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | Phase 3 |
Mechanism of action
Glycerol is a small polyol that creates an osmotic gradient, pulling water from tissues into the vascular space and reducing brain edema. It is metabolized slowly, allowing sustained osmotic effect. The drug is used primarily to manage elevated intracranial pressure in acute neurological conditions.
Approved indications
- Elevated intracranial pressure
- Cerebral edema
Common side effects
- Hyperglycemia
- Dehydration
- Rebound intracranial pressure elevation
- Headache
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Glycerol "OBA" CI brief — competitive landscape report
- Glycerol "OBA" updates RSS · CI watch RSS
- University of Aarhus portfolio CI